2023
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi S, Riaz I, He H, Imran M, Orme J, Childs D, Ravi P, Hussain S, Singh P, Bryce A. The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. Journal Of Clinical Oncology 2023, 41: 5088-5088. DOI: 10.1200/jco.2023.41.16_suppl.5088.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerVolume of diseaseTriplet therapyDoublet therapyLV diseaseHazard ratioCastration-sensitive prostate cancerSensitive prostate cancerLow-volume diseaseEfficacious treatment optionConfidence intervalsInverse variance approachMixed treatment comparisonMCSPC patientsTreatment intensificationTreatment optionsClinical trialsProstate cancerEfficacious treatmentTreatment selectionDisease subgroupsPatientsComparative effectivenessTherapyDiseaseA living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).
Bin Riaz I, Naqvi S, He H, Siddiqi R, Asghar N, Ravi P, Hussain S, Singh P, Bryce A. A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC). Journal Of Clinical Oncology 2023, 41: 193-193. DOI: 10.1200/jco.2023.41.6_suppl.193.Peer-Reviewed Original ResearchProgression-free survivalMetastatic castration-sensitive prostate cancerAndrogen pathway inhibitorsMCSPC patientsTriplet regimensHazard ratioSignificant improved progression-free survivalCastration-sensitive prostate cancerImproved progression-free survivalSubgroup dataOverall patient populationTiming of metastasisConfidence intervalsVolume of diseaseMixed treatment comparisonEvidence synthesis frameworkSTAMPEDE trialTreatment intensificationTriplet regimenDisease volumeMetastatic presentationSystemic therapyOptimal therapyRandomized comparisonPatient population
2022
Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
Sipra Q, Bin Riaz I, Naqvi S, He H, Liu H, Bryce A, Murad M, McBane R. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis. Journal Of Clinical Oncology 2022, 40: e24070-e24070. DOI: 10.1200/jco.2022.40.16_suppl.e24070.Peer-Reviewed Original ResearchNet clinical benefitMixed treatment comparisonMajor bleedingClinical benefitSystematic reviewCANVAS trialOdds ratioGreater net clinical benefitRelevant non-major bleedingSignificant differencesTreatment comparisonsEffect estimatesEfficacy of DOACsNon-major bleedingVTE risk reductionVenous thromboembolism recurrenceCumulative ranking curvePatient-important outcomesConfidence intervalsMantel-Haenszel methodTreatment of catsFixed-effects modelThromboembolism recurrenceVTE recurrenceCause mortality